Hiba Sayed, MD
Internal Medicine · New York, NYNPI 1487158663
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 59 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations.
Across 59 payments — averaging $20.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$234
- AbbVie$196
- Pfizer$172
- Biohaven Pharmaceutical Holding Company Ltd.$89
- GSK$88
- Merck$87
- plus $322 from 11 others
What the payments were for
- Food & beverage$1,188100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 13 | $234 |
| AbbVie | 7 | $196 |
| Pfizer | 9 | $172 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $89 |
| GSK | 5 | $88 |
| Merck | 4 | $87 |
| Exact Sciences | 3 | $65 |
| Lilly USA, LLC | 3 | $48 |
| AstraZeneca | 2 | $31 |
| Johnson & Johnson | 1 | $26 |
| IBSA Pharma Inc. | 1 | $25 |
| Upsher-smith Laboratories LLC | 1 | $24 |
| Idorsia Pharmaceuticals US Inc | 1 | $23 |
| Eisai Inc. | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Mylan Specialty L.p. | 1 | $20 |
| Grifols USA, LLC | 1 | $17 |
How this compares
$1,188 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rosuvastatin Calcium | 41 | $1,203 |
| Atorvastatin Calcium | 58 | $678 |
| Levothyroxine Sodium | 33 | $452 |
| Metformin Hcl | 22 | $278 |
| Losartan Potassium | 36 | $261 |
| Lisinopril | 16 | $236 |
| Escitalopram Oxalate | 16 | $217 |
| Amlodipine Besylate | 30 | $203 |
| Omeprazole | 12 | $195 |
| Hydrochlorothiazide | 13 | $96 |
| Trazodone Hcl | 11 | $80 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in New York
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Ricky HsuNew York$1M
- James UnderbergNew York$953K
- Terry PlasseNew York$883K
- Krisczar BungayNew York$554K
- Eytan SteinNew York$496K
- Larry NeumanNew York$457K
- Wuhua JingNew York$338K
- Harvey SchneienNew York$334K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.